{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:26:17Z","timestamp":1777685177673,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2020,2,10]]},"DOI":"10.3233\/jhd-190391","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T12:23:50Z","timestamp":1579868630000},"page":"47-58","source":"Crossref","is-referenced-by-count":2,"title":["Baseline Variables Associated with Functional Decline in 2CARE, A Randomized Clinical Trial in Huntington\u2019s Disease"],"prefix":"10.1177","volume":"9","author":[{"given":"Andrew","family":"McGarry","sequence":"first","affiliation":[{"name":"Cooper University Healthcare at Rowan University, Camden, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Huntington Study Group 2CARE Investigators and Coordinators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"McDermott","sequence":"additional","affiliation":[{"name":"University of Rochester, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Kieburtz","sequence":"additional","affiliation":[{"name":"University of Rochester, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merit","family":"Cudkowicz","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"2","key":"10.3233\/JHD-190391_ref2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.870100213","article-title":"Functional decline in Huntington\u2019s disease","volume":"10","author":"Feigin","year":"1995","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-190391_ref3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1212\/WNL.54.2.452","article-title":"Rate of functional decline in Huntington\u2019s disease","volume":"54","author":"Marder","year":"2000","journal-title":"Neurology"},{"issue":"12","key":"10.3233\/JHD-190391_ref4","first-page":"1520","article-title":"Natural history of Huntington disease","volume":"70","author":"Dorsey","year":"2013","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.3233\/JHD-190391_ref5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-190391_ref6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington\u2019s disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.3233\/JHD-190391_ref7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1750-1172-6-77","article-title":"Coordinated multidisciplinary care for ambulatory Huntington\u2019s disease patients: Evaluation of 18 months of implementation","volume":"6","author":"Veenhuizen","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.3233\/JHD-190391_ref8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-170260","article-title":"Physical therapy and exercise interventions in Huntington\u2019s disease: A mixed methods systematic review","volume":"6","author":"Fritz","year":"2017","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-190391_ref9","unstructured":"Piira A , van Walsem MR , Mikalsen G , Nilsen KH , Knutsen S , Frich JC . Effects of a one year intensive multidisciplinary rehabilitation program for patients with Huntington\u2019s disease: A prospective intervention study. PLoS Curr. 2013;5: ecurrents.hd.9504af71e0d1f87830c25c394be47027."},{"issue":"11","key":"10.3233\/JHD-190391_ref10","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1136\/jmg.31.11.872","article-title":"Trinucleotide repeat length and progression of illness in Huntington\u2019s disease","volume":"31","author":"Kieburtz","year":"1994","journal-title":"J Med Genet"},{"key":"10.3233\/JHD-190391_ref11","first-page":"136","article-title":"Huntington Study Group","volume":"11","author":"The Unified Huntington\u2019s Disease Rating Scale: Reliability and consistency","year":"1996","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-190391_ref13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s Disease","volume":"57","author":"The Huntington Study Group","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.3233\/JHD-190391_ref14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington\u2019s disease: A 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"issue":"6","key":"10.3233\/JHD-190391_ref15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST-E study of creatine for Huntington disease: A randomized controlled trial","volume":"89","author":"Hersch","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.3233\/JHD-190391_ref16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","article-title":"Earliest functional declines in Huntington disease","volume":"178","author":"Beglinger","year":"2010","journal-title":"Psychiatry Res"},{"issue":"14","key":"10.3233\/JHD-190391_ref17","doi-asserted-by":"publisher","first-page":"e1643","DOI":"10.1212\/WNL.0000000000007244","article-title":"Risk factors for suicidality in Huntington\u2019s disease: An analysis of the 2CARE Clinical Trial","volume":"92","author":"McGarry","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JHD-190391_ref18","doi-asserted-by":"crossref","unstructured":"Molenberghs G , Kenward MG . Missing data in clinical studies. Chichester, UK: John Wiley and Sons; 2007.","DOI":"10.1002\/9780470510445"},{"key":"10.3233\/JHD-190391_ref19","first-page":"509","article-title":"Neuroprotective role of testosterone in the nervous system","volume":"56","author":"Bialek","year":"2004","journal-title":"Pol J Pharmacol"},{"issue":"5","key":"10.3233\/JHD-190391_ref20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.steroids.2007.02.003","article-title":"Neurotrophic and neuroprotective actions of estrogen: Basic mechanisms and clinical implications","volume":"72","author":"Brann","year":"2007","journal-title":"Steroids"},{"issue":"2","key":"10.3233\/JHD-190391_ref21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.yhbeh.2012.06.003","article-title":"Progesterone and neuroprotection","volume":"63","author":"Singh","year":"2013","journal-title":"Horm Behav"},{"issue":"4","key":"10.3233\/JHD-190391_ref22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.20428","article-title":"Plasma testosterone in male patients with Huntington\u2019s Disease; relations to severity of illness and dementia","volume":"57","author":"Markianos","year":"2005","journal-title":"Ann Neurol"},{"key":"10.3233\/JHD-190391_ref23","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1460-9568.2005.04324.x","article-title":"Reduction of GnRH and infertility in the R6 \/ 2 mouse model of Huntington\u2019s disease","volume":"22","author":"Papalexi","year":"2005","journal-title":"Eur J Neurosci"},{"key":"10.3233\/JHD-190391_ref24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2826.2011.02238.x","article-title":"Deficits in spermatogenesis but not neurogenesis are alleviated by chronic testosterone therapy in R6 \/ 1 Huntington\u2019s disease mice","volume":"24","author":"Hannan","year":"2012","journal-title":"J Neuroendocrinol"},{"issue":"4 Suppl","key":"10.3233\/JHD-190391_ref25","doi-asserted-by":"crossref","first-page":"P360","DOI":"10.1016\/j.jalz.2013.05.686","article-title":"P2\u2013044: Neuroprotective role of progesterone against 3-nitropropionic acid-induced Huntington\u2019s disease-like symptoms in rats","volume":"9","author":"Kumar","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.3233\/JHD-190391_ref26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.4103\/1673-5374.179045","article-title":"Estrogen\/Huntingtin: A novel pathway involved in neuroprotection","volume":"11","author":"Nuzzo","year":"2016","journal-title":"Neural Regen Res"},{"key":"10.3233\/JHD-190391_ref27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neures.2015.07.013","article-title":"17\u03b2-Estradiol modulates huntingtin levels in rat tissues and in human neuroblastoma cell line","volume":"103","author":"Nuzzo","year":"2016","journal-title":"Neurosci Res"},{"key":"10.3233\/JHD-190391_ref28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.parkreldis.2018.01.006","article-title":"The contribution of gender differences in motor, behavioral, and cognitive features to functional capacity independence and quality of life in patients with Huntington\u2019s disease","volume":"49","author":"Zielonka","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"10.3233\/JHD-190391_ref29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.870100213","article-title":"Functional decline in Huntington\u2019s disease","volume":"10","author":"Feigin","year":"1995","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-190391_ref30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.46.2.527","article-title":"Trinucleotide repeat length and clinical progression in Huntington\u2019s disease","volume":"46","author":"Brandt","year":"1996","journal-title":"Neurology"},{"issue":"9","key":"10.3233\/JHD-190391_ref31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/mds.21988","article-title":"The relationship between CAG repeat length and clinical progression in Huntington\u2019s disease","volume":"23","author":"Ravina","year":"2008","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-190391_ref32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/mds.24024","article-title":"Age, CAG repeat length, and clinical progression in Huntington\u2019s disease","volume":"27","author":"Rosenblatt","year":"2012","journal-title":"Mov Disord"},{"key":"10.3233\/JHD-190391_ref33","doi-asserted-by":"crossref","first-page":"e2099","DOI":"10.1212\/WNL.0000000000005690","article-title":"Overlap between age-at-onset and disease-progression determinants in Huntington disease","volume":"90","author":"Aziz","year":"2018","journal-title":"Neurology"},{"key":"10.3233\/JHD-190391_ref34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.omtn.2018.03.008","article-title":"Novel DNA Aptamers that bind to mutant Huntingtin and modify its activity","volume":"11","author":"Shin","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"issue":"19","key":"10.3233\/JHD-190391_ref35","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1093\/hmg\/ddx286","article-title":"A modifier of Huntington\u2019s disease onset at the MLH1 locus","volume":"26","author":"Lee","year":"2017","journal-title":"Hum Mol Genet"},{"key":"10.3233\/JHD-190391_ref36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of genetic factors that modify clinical onset of Huntington\u2019s disease","volume":"162","author":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.3233\/JHD-190391_ref37","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: A genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-190391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:50:59Z","timestamp":1777452659000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-190391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":35,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jhd-190391","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]}}}